Inclisiran | List of Frontiers open access articles

Original Research

Published on 26 Feb 2024

The combination use of inclisiran and statins versus statins alone in the treatment of dyslipidemia in mainland China: a cost-effectiveness analysis

in Pharmacoepidemiology

Wenjing Zhou
Zhuoru Liang
Xiaohuan Lou
Nansong Wang
Xinyu Liu
Ruoxi Li
Pearl Pai

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1283922

7,163 views
9 citations

Original Research

Published on 15 Jul 2025

Systemic evaluation of inclisiran on the risk of new-onset diabetes and hyperglycemia compared to evolocumab and atorvastatin

in Pharmacoepidemiology

Fei Li
Huan Ye
Lingbin Chen
Yuanchun Ma
Sunhui Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1554631

4,288 views
1 citation

Review

Published on 13 Oct 2023

Inclisiran: a new generation of lipid-lowering siRNA therapeutic

in Cardiovascular and Smooth Muscle Pharmacology

Yanzhen Zhang
Huaigang Chen
Lang Hong
Hong Wang
Bin Li
Mengyin Zhang
Jiamei Li
Liu Yang
Fan Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1260921

38,744 views
46 citations

Case Report

Published on 17 Sep 2024

Challenges in the management of familial hypercholesterolemia: a case report

in Lipids in Cardiovascular Disease

Joanna Rogozik
Marcin Grabowski
Renata Główczyńska

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2024.1417432

3,755 views

Review

Published on 14 Feb 2025

Current usage of inclisiran for cardiovascular diseases: overview of current clinical trials

in Cardiovascular and Smooth Muscle Pharmacology

Maan H. Harbi

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1449712

9,012 views
10 citations

Systematic Review

Published on 13 Jun 2023

Efficacy and safety of inclisiran in stroke or cerebrovascular disease prevention: a systematic review and meta-analysis of randomized controlled trials

in Neuropharmacology

Min Luo
Yihan Liu
Xinyi Xu
Kai Liu
Chao Shen
Haoyang Hu
Zhiyao He
Fengbo Wu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1158274

11,690 views
25 citations

Review

Published on 17 Nov 2021

Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol

in Lipids in Cardiovascular Disease

Chandni Bardolia
Nishita Shah Amin
Jacques Turgeon

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2021.789931

65,508 views
60 citations

Review

Published on 25 Apr 2022

Non-coding RNA-Associated Therapeutic Strategies in Atherosclerosis

in Cardiovascular Metabolism

Yuyan Tang
Huaping Li
Chen Chen

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2022.889743

6,318 views
6 citations

Case Report

Published on 23 Jun 2023

Painful and recurring injection site reaction to alirocumab and evolocumab in a young woman with familial hypercholesterolemia and effective therapeutic alternative based on inclisiran: a case report

in Lipids in Cardiovascular Disease

Massimiliano Allevi
Silvia Sarnari
Federico Giulietti
Francesco Spannella
Chiara Di Pentima
Riccardo Sarzani

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2023.1181720

6,454 views
3 citations

Original Research

Published on 22 Aug 2025

Efficacy and safety of different proprotein convertase subtilisin/kexin type 9 inhibitors in the general population and solid organ transplant recipients: a network meta-analysis

in Drugs Outcomes Research and Policies

Bohan Luo
Zhuang Sun
Han Luo

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1584612

2,595 views

Systematic Review

Published on 03 Jun 2024

Global trends and research hotspots of PCSK9 and cardiovascular disease: a bibliometric and visual analysis

in Cardiovascular Epidemiology and Prevention

Masong Tang
Sen Yang
Junying Zou
Meng Li
Yan Sun
Mengqi Wang
Wanhan Li
Junhui He
Ying Chen
Zhanyou Tang

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2024.1336264

5,147 views
5 citations

Systematic Review

Published on 08 Jul 2024

PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a systematic review and network meta-analysis

in Atherosclerosis and Vascular Medicine

Wenshu Li
Lichaoyue Sun
Sichao Yan

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2024.1375040

6,795 views
3 citations

Review

Published on 09 Jun 2022

The Progression of Treatment for Refractory Hypercholesterolemia: Focus on the Prospect of Gene Therapy

in Genetics of Common and Rare Diseases

Zhi-Fan Li
Na-Qiong Wu

Frontiers in Genetics

doi 10.3389/fgene.2022.911429

12,109 views
8 citations

Original Research

Published on 19 Nov 2025

Cost-utility analysis of PCSK9 inhibitors for hypercholesterolemia: a Chinese healthcare perspective

in Drugs Outcomes Research and Policies

Dandan Hu
Xu Deng
Mengwen Feng
Xinyue Zhang
Qingfeng He
Tao Wang
Zhen Feng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1708701

2,378 views

Systematic Review

Published on 05 Feb 2025

Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis

in Lipids in Cardiovascular Disease

Yuhua Jiang
Yingying Wang
Sijia Ma
Linlin Qian
Yeteng Jing
Xi Chen
Jinsheng Yang

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2024.1415668

12,044 views
6 citations

Articles

The combination use of inclisiran and statins versus statins alone in the treatment of dyslipidemia in mainland China: a cost-effectiveness analysis

Systemic evaluation of inclisiran on the risk of new-onset diabetes and hyperglycemia compared to evolocumab and atorvastatin

Inclisiran: a new generation of lipid-lowering siRNA therapeutic

Challenges in the management of familial hypercholesterolemia: a case report

Current usage of inclisiran for cardiovascular diseases: overview of current clinical trials

Efficacy and safety of inclisiran in stroke or cerebrovascular disease prevention: a systematic review and meta-analysis of randomized controlled trials

Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol

Non-coding RNA-Associated Therapeutic Strategies in Atherosclerosis

Painful and recurring injection site reaction to alirocumab and evolocumab in a young woman with familial hypercholesterolemia and effective therapeutic alternative based on inclisiran: a case report

Efficacy and safety of different proprotein convertase subtilisin/kexin type 9 inhibitors in the general population and solid organ transplant recipients: a network meta-analysis

Global trends and research hotspots of PCSK9 and cardiovascular disease: a bibliometric and visual analysis

PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a systematic review and network meta-analysis

The Progression of Treatment for Refractory Hypercholesterolemia: Focus on the Prospect of Gene Therapy

Cost-utility analysis of PCSK9 inhibitors for hypercholesterolemia: a Chinese healthcare perspective

Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis